20.2% for Pradaxa ® 150 mg dual-therapy versus 25.7% for warfarin triple therapy, which translates into a 28% lower risk Both Pradaxa ® dual therapy groups also showed lower rates of major bleeding ...
Ridgefield, CT, April 6, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for ...
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...
Ridgefield, Conn., Boehringer Ingelheim today announced results from a retrospective, observational real-world study assessing the safety and effectiveness of novel oral anticoagulants (NOACs) among ...
RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...
RIDGEFIELD, Conn., June 26, 2014 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...
Alembic has received the Food and Drug Administration’s permission for Dabigatran Etexilate Capsules, 75 mg and 150 mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg. The approved ...
Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010. Pradaxa is approved by the FDA to reduce the risk ...
Treatment is reportedly the first new oral anticoagulant approved in the U.S. for over 50 years. FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor Pradaxa® (dabigatran etexilate) ...
Direct thrombin inhibitor is cleared in U.S., Canada, Japan, and Australia for the same indication. The European Commission cleared Boehringer Ingelheim’s oral anticoagulant Pradaxa® (dabigatran ...
RIDGEFIELD, Conn., April 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa ® (dabigatran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results